Product Description
S-777469 is an orally available CB2 agonist as an antipruritic agent. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22444677/)
Mechanisms of Action: CB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shionogi
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00703573 |
0721D1424 | P2 |
Completed |
Dermatitis, Atopic |
2009-05-01 |
2019-03-18 |
Treatments |
|
NCT00697710 |
0710D1416 | P2 |
Completed |
Dermatitis, Atopic |
2008-02-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|